These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 25555492

  • 21. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ, Malkin SJP, Martín V, Hallén N, Hunt B.
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [Abstract] [Full Text] [Related]

  • 22. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D, Chbib S, Kaddoura R, Al Hail M, Abdul Rouf PV, El Kassem W, Shah J, Ravindran Nair RK, Al-Badriyeh D.
    J Med Econ; 2024 Feb; 27(1):404-417. PubMed ID: 38390641
    [Abstract] [Full Text] [Related]

  • 23. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
    Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, Liew D.
    Sci Rep; 2019 Mar 01; 9(1):3256. PubMed ID: 30824788
    [Abstract] [Full Text] [Related]

  • 24. Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis.
    Cortesi PA, Antonazzo IC, Palladino P, Gnesi M, Mele S, D'Amelio M, Zanzottera Ferrari E, Mazzaglia G, Mantovani LG.
    Acta Diabetol; 2024 Aug 01; 61(8):1017-1028. PubMed ID: 38634912
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction.
    Parizo JT, Goldhaber-Fiebert JD, Salomon JA, Khush KK, Spertus JA, Heidenreich PA, Sandhu AT.
    JAMA Cardiol; 2021 Aug 01; 6(8):926-935. PubMed ID: 34037681
    [Abstract] [Full Text] [Related]

  • 26. [Dapagliflozin, a novel oral antidiabetic with an uncertain future].
    Escudero Vilaplana B, Almodóvar Carretón MJ, Herrero Hernández S.
    Farm Hosp; 2014 Nov 03; 38(6):468-74. PubMed ID: 25542657
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Klarenbach S, Cameron C, Singh S, Ur E.
    CMAJ; 2011 Nov 08; 183(16):E1213-20. PubMed ID: 21969406
    [Abstract] [Full Text] [Related]

  • 28. Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study.
    Norhammar A, Bodegard J, Nyström T, Thuresson M, Rikner K, Nathanson D, Eriksson JW.
    Diabetes Obes Metab; 2019 Dec 08; 21(12):2651-2659. PubMed ID: 31379124
    [Abstract] [Full Text] [Related]

  • 29. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ, Lee DH, Jeon HJ, Oh TK.
    Diabetes Res Clin Pract; 2019 May 08; 151():65-73. PubMed ID: 30954510
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes.
    Pawaskar M, Bilir SP, Kowal S, Gonzalez C, Rajpathak S, Davies G.
    Am J Manag Care; 2019 May 08; 25(5):231-238. PubMed ID: 31120717
    [Abstract] [Full Text] [Related]

  • 33. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G.
    Diabetes Obes Metab; 2019 Nov 08; 21(11):2564-2569. PubMed ID: 31364269
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT, Yang CT, Toh HS, Chang WT, Chang HY, Kuo FH, Lee MC, Hua YM, Tang HJ, Strong C, Ou HT.
    Cardiovasc Diabetol; 2021 Oct 09; 20(1):204. PubMed ID: 34627231
    [Abstract] [Full Text] [Related]

  • 35. Dapagliflozin combination therapy in type 2 diabetes mellitus.
    Yacoub T.
    Postgrad Med; 2016 Jan 09; 128(1):124-36. PubMed ID: 26571022
    [Abstract] [Full Text] [Related]

  • 36. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N, Calvachi P, Raber I, Liu CL, Bellows BK, Hernandez I, Shen C, Gavin MC, Garan AR, Kazi DS.
    JAMA Netw Open; 2021 Jul 01; 4(7):e2114501. PubMed ID: 34313742
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S, Deng J, Shi L, Mu Y, Dong H.
    J Med Econ; 2015 Jul 01; 18(10):808-20. PubMed ID: 25950193
    [Abstract] [Full Text] [Related]

  • 38. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.
    Pharmacoeconomics; 2006 Jul 01; 24 Suppl 1():49-59. PubMed ID: 16800162
    [Abstract] [Full Text] [Related]

  • 39. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S, Deng X, Ma Y, Li Z, Wang Y, Wang Y.
    Appl Health Econ Health Policy; 2021 Jan 01; 19(1):69-79. PubMed ID: 32783086
    [Abstract] [Full Text] [Related]

  • 40. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
    Garnock-Jones KP.
    Drugs; 2017 Mar 01; 77(3):319-330. PubMed ID: 28176222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.